| Inflammatory Bowel Disease | Lifetime | 31 | US 10 | 99.78 |
| Microscopic Colitis | Lifetime | 32 | US 10 | 99.75 |
| Autoimmune and Inflammatory Disorders | Lifetime | 19 | US 6 | 99.53 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 236 | US 81 | 98.91 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 208 | US 94 | 98.89 |
| Biosimilars and Bioanalytical Methods | Lifetime | 57 | US 18 | 98.48 |
| Eosinophilic Esophagitis | Lifetime | 172 | US 72 | 98.94 |
| COVID-19 and healthcare impacts | Lifetime | 246 | US 96 | 96.48 |
| Colorectal Cancer Screening and Detection | Lifetime | 340 | US 158 | 98.59 |
| Diverticular Disease and Complications | Lifetime | 192 | US 87 | 98.20 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 238 | US 115 | 98.08 |
| Diagnosis and treatment of tuberculosis | Lifetime | 177 | US 48 | 97.68 |
| Pregnancy and Medication Impact | Lifetime | 269 | US 117 | 96.98 |
| Liver Diseases and Immunity | Lifetime | 318 | US 100 | 97.53 |
| Gastrointestinal motility and disorders | Lifetime | 486 | US 172 | 96.74 |
| Pharmaceutical studies and practices | Lifetime | 612 | US 275 | 96.04 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 675 | US 189 | 96.03 |
| Celiac Disease Research and Management | Lifetime | 427 | US 101 | 94.80 |
| Gastrointestinal Bleeding Diagnosis and Treatment | Lifetime | 520 | US 141 | 93.04 |
| Whipple's Disease and Interleukins | Lifetime | 463 | US 137 | 68.22 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 929 | US 271 | 65.76 |
| Inflammatory Bowel Disease | 2021-2025 | 7 | US 3 | 99.92 |
| Microscopic Colitis | 2021-2025 | 5 | US 2 | 99.92 |
| Eosinophilic Esophagitis | 2021-2025 | 8 | US 4 | 99.62 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 16 | US 5 | 99.37 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 6 | US 2 | 99.53 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 24 | US 3 | 96.08 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 81 | US 23 | 97.03 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 53 | US 20 | 96.36 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 184 | US 68 | 96.53 |
| Diverticular Disease and Complications | 2021-2025 | 77 | US 24 | 94.37 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 154 | US 38 | 96.30 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 780 | US 254 | 94.04 |
| Liver Diseases and Immunity | 2021-2025 | 184 | US 50 | 93.69 |
| Gastrointestinal motility and disorders | 2021-2025 | 221 | US 58 | 92.40 |
| Pregnancy and Medication Impact | 2021-2025 | 252 | US 82 | 89.05 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 326 | US 114 | 86.55 |
| Celiac Disease Research and Management | 2021-2025 | 193 | US 33 | 87.49 |
| Adolescent and Pediatric Healthcare | 2021-2025 | 616 | US 249 | 84.13 |
| Pharmaceutical studies and practices | 2021-2025 | 474 | US 155 | 82.87 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 694 | US 201 | 82.14 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 928 | US 45 | 78.91 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 392 | US 124 | 70.10 |
| Gastrointestinal Bleeding Diagnosis and Treatment | 2021-2025 | 608 | US 80 | 71.11 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 418 | US 134 | 66.61 |
